Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice

Ken L. Chambliss, Jose Barrera, Michihisa Umetani, Junko Umetani, Sung Hoon Kim, Zeynep Madak-Erdogan, Linzhang Huang, Benita S. Katzenellenbogen, John A. Katzenellenbogen, Chieko Mineo, Philip W. Shaul

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Estrogens have the potential to afford atheroprotection, to prevent excess adiposity and its metabolic complications including insulin resistance, and to lessen hepatic steatosis. Cellular responses to estrogens occur through gene regulation by nuclear estrogen receptors (ERs), and through signal initiation by plasma membrane-associated ER. Leveraging the potentially favorable cardiometabolic actions of estrogens has been challenging, because their reproductive tract and cancerpromoting effects adversely impact the risk to benefit ratio of the therapy. In previous works, we discovered that an estrogen dendrimer conjugate (EDC) comprised of ethinyl-estradiol (E2) molecules linked to a poly(amido)amine dendrimer selectively activates nonnuclear ER, and in mice, EDC does not invoke a uterotrophic response or support ER-positive breast cancer growth. In the present investigation, we employed EDC to determine how selective nonnuclear ER activation impacts atherosclerosis, adiposity, glucose homeostasis, and hepatic steatosis in female mice. In contrast to E2, EDC did not blunt atherosclerosis in hypercholesterolemic apoE-/- mice. Also in contrast to E2, EDC did not prevent the increase in adiposity caused by Western diet feeding in wild-type mice, and it did not affect Western diet-induced glucose intolerance. However, E2 and EDC had comparable favorable effect on diet-induced hepatic steatosis, and this was related to down-regulation of fatty acid and triglyceride synthesis genes in the liver. Predictably, only E2 caused a uterotrophic response. Thus, although nonnuclear ER activation does not prevent atherosclerosis or diet-induced obesity or glucose intolerance, it may provide a potential new strategy to combat hepatic steatosis without impacting the female reproductive tract or increasing cancer risk.

Original languageEnglish (US)
Pages (from-to)3731-3741
Number of pages11
JournalEndocrinology
Volume157
Issue number10
DOIs
StatePublished - 2016

Fingerprint

Dendrimers
Estrogen Receptors
Estrogens
Liver
Adiposity
Atherosclerosis
Glucose Intolerance
Diet
Ethinyl Estradiol
Apolipoproteins E
Genes
Amines
Insulin Resistance
Triglycerides
Homeostasis
Fatty Acids
Down-Regulation
Obesity
Cell Membrane
Breast Neoplasms

ASJC Scopus subject areas

  • Endocrinology

Cite this

Chambliss, K. L., Barrera, J., Umetani, M., Umetani, J., Kim, S. H., Madak-Erdogan, Z., ... Shaul, P. W. (2016). Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice. Endocrinology, 157(10), 3731-3741. https://doi.org/10.1210/en.2015-1629

Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice. / Chambliss, Ken L.; Barrera, Jose; Umetani, Michihisa; Umetani, Junko; Kim, Sung Hoon; Madak-Erdogan, Zeynep; Huang, Linzhang; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.; Mineo, Chieko; Shaul, Philip W.

In: Endocrinology, Vol. 157, No. 10, 2016, p. 3731-3741.

Research output: Contribution to journalArticle

Chambliss, KL, Barrera, J, Umetani, M, Umetani, J, Kim, SH, Madak-Erdogan, Z, Huang, L, Katzenellenbogen, BS, Katzenellenbogen, JA, Mineo, C & Shaul, PW 2016, 'Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice', Endocrinology, vol. 157, no. 10, pp. 3731-3741. https://doi.org/10.1210/en.2015-1629
Chambliss KL, Barrera J, Umetani M, Umetani J, Kim SH, Madak-Erdogan Z et al. Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice. Endocrinology. 2016;157(10):3731-3741. https://doi.org/10.1210/en.2015-1629
Chambliss, Ken L. ; Barrera, Jose ; Umetani, Michihisa ; Umetani, Junko ; Kim, Sung Hoon ; Madak-Erdogan, Zeynep ; Huang, Linzhang ; Katzenellenbogen, Benita S. ; Katzenellenbogen, John A. ; Mineo, Chieko ; Shaul, Philip W. / Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice. In: Endocrinology. 2016 ; Vol. 157, No. 10. pp. 3731-3741.
@article{7d8bc466cf9d46c5b14215a057ec5a02,
title = "Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice",
abstract = "Estrogens have the potential to afford atheroprotection, to prevent excess adiposity and its metabolic complications including insulin resistance, and to lessen hepatic steatosis. Cellular responses to estrogens occur through gene regulation by nuclear estrogen receptors (ERs), and through signal initiation by plasma membrane-associated ER. Leveraging the potentially favorable cardiometabolic actions of estrogens has been challenging, because their reproductive tract and cancerpromoting effects adversely impact the risk to benefit ratio of the therapy. In previous works, we discovered that an estrogen dendrimer conjugate (EDC) comprised of ethinyl-estradiol (E2) molecules linked to a poly(amido)amine dendrimer selectively activates nonnuclear ER, and in mice, EDC does not invoke a uterotrophic response or support ER-positive breast cancer growth. In the present investigation, we employed EDC to determine how selective nonnuclear ER activation impacts atherosclerosis, adiposity, glucose homeostasis, and hepatic steatosis in female mice. In contrast to E2, EDC did not blunt atherosclerosis in hypercholesterolemic apoE-/- mice. Also in contrast to E2, EDC did not prevent the increase in adiposity caused by Western diet feeding in wild-type mice, and it did not affect Western diet-induced glucose intolerance. However, E2 and EDC had comparable favorable effect on diet-induced hepatic steatosis, and this was related to down-regulation of fatty acid and triglyceride synthesis genes in the liver. Predictably, only E2 caused a uterotrophic response. Thus, although nonnuclear ER activation does not prevent atherosclerosis or diet-induced obesity or glucose intolerance, it may provide a potential new strategy to combat hepatic steatosis without impacting the female reproductive tract or increasing cancer risk.",
author = "Chambliss, {Ken L.} and Jose Barrera and Michihisa Umetani and Junko Umetani and Kim, {Sung Hoon} and Zeynep Madak-Erdogan and Linzhang Huang and Katzenellenbogen, {Benita S.} and Katzenellenbogen, {John A.} and Chieko Mineo and Shaul, {Philip W.}",
year = "2016",
doi = "10.1210/en.2015-1629",
language = "English (US)",
volume = "157",
pages = "3731--3741",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Nonnuclear estrogen receptor activation improves hepatic steatosis in female mice

AU - Chambliss, Ken L.

AU - Barrera, Jose

AU - Umetani, Michihisa

AU - Umetani, Junko

AU - Kim, Sung Hoon

AU - Madak-Erdogan, Zeynep

AU - Huang, Linzhang

AU - Katzenellenbogen, Benita S.

AU - Katzenellenbogen, John A.

AU - Mineo, Chieko

AU - Shaul, Philip W.

PY - 2016

Y1 - 2016

N2 - Estrogens have the potential to afford atheroprotection, to prevent excess adiposity and its metabolic complications including insulin resistance, and to lessen hepatic steatosis. Cellular responses to estrogens occur through gene regulation by nuclear estrogen receptors (ERs), and through signal initiation by plasma membrane-associated ER. Leveraging the potentially favorable cardiometabolic actions of estrogens has been challenging, because their reproductive tract and cancerpromoting effects adversely impact the risk to benefit ratio of the therapy. In previous works, we discovered that an estrogen dendrimer conjugate (EDC) comprised of ethinyl-estradiol (E2) molecules linked to a poly(amido)amine dendrimer selectively activates nonnuclear ER, and in mice, EDC does not invoke a uterotrophic response or support ER-positive breast cancer growth. In the present investigation, we employed EDC to determine how selective nonnuclear ER activation impacts atherosclerosis, adiposity, glucose homeostasis, and hepatic steatosis in female mice. In contrast to E2, EDC did not blunt atherosclerosis in hypercholesterolemic apoE-/- mice. Also in contrast to E2, EDC did not prevent the increase in adiposity caused by Western diet feeding in wild-type mice, and it did not affect Western diet-induced glucose intolerance. However, E2 and EDC had comparable favorable effect on diet-induced hepatic steatosis, and this was related to down-regulation of fatty acid and triglyceride synthesis genes in the liver. Predictably, only E2 caused a uterotrophic response. Thus, although nonnuclear ER activation does not prevent atherosclerosis or diet-induced obesity or glucose intolerance, it may provide a potential new strategy to combat hepatic steatosis without impacting the female reproductive tract or increasing cancer risk.

AB - Estrogens have the potential to afford atheroprotection, to prevent excess adiposity and its metabolic complications including insulin resistance, and to lessen hepatic steatosis. Cellular responses to estrogens occur through gene regulation by nuclear estrogen receptors (ERs), and through signal initiation by plasma membrane-associated ER. Leveraging the potentially favorable cardiometabolic actions of estrogens has been challenging, because their reproductive tract and cancerpromoting effects adversely impact the risk to benefit ratio of the therapy. In previous works, we discovered that an estrogen dendrimer conjugate (EDC) comprised of ethinyl-estradiol (E2) molecules linked to a poly(amido)amine dendrimer selectively activates nonnuclear ER, and in mice, EDC does not invoke a uterotrophic response or support ER-positive breast cancer growth. In the present investigation, we employed EDC to determine how selective nonnuclear ER activation impacts atherosclerosis, adiposity, glucose homeostasis, and hepatic steatosis in female mice. In contrast to E2, EDC did not blunt atherosclerosis in hypercholesterolemic apoE-/- mice. Also in contrast to E2, EDC did not prevent the increase in adiposity caused by Western diet feeding in wild-type mice, and it did not affect Western diet-induced glucose intolerance. However, E2 and EDC had comparable favorable effect on diet-induced hepatic steatosis, and this was related to down-regulation of fatty acid and triglyceride synthesis genes in the liver. Predictably, only E2 caused a uterotrophic response. Thus, although nonnuclear ER activation does not prevent atherosclerosis or diet-induced obesity or glucose intolerance, it may provide a potential new strategy to combat hepatic steatosis without impacting the female reproductive tract or increasing cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=84990946965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990946965&partnerID=8YFLogxK

U2 - 10.1210/en.2015-1629

DO - 10.1210/en.2015-1629

M3 - Article

VL - 157

SP - 3731

EP - 3741

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 10

ER -